Jinjun Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinjun Ye has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Zhi Zhang
Department of Clinical Oncology, Cancer Hospital of Nanjing Medical University, Nanjing, China
16 shared publicationsYing Fang
Department of Clinical Oncology, Cancer Hospital of Nanjing Medical University, Nanjing, China
13 shared publicationsDayong Gu
Department of Clinical Oncology, Cancer Hospital of Nanjing Medical University, Nanjing, China
10 shared publicationsGuoren Zhou
Department of Clinical Oncology, Cancer Hospital of Nanjing Medical University, Nanjing, China
10 shared publicationsHui Li
Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
8 shared publicationsTian Wang
Xuzhou Cancer Hospital, Xuzhou, China
8 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Treatment Patterns and Neuroendocrine Markers in Esophageal Small Cell Carcinoma: A Multicenter Retrospective Study
Objective: To evaluate the treatment patterns, prognostic factors, and the prognostic value of neuroendocrine markers in primary small cell carcinoma of the esophagus (PSCCE).Methods: A total of 217 patients with PSCCE treated at three centers—the Affiliated Cancer Hospital of Nanjing Medical University, the Affiliated Taizhou Hospital of Nanjing Medical University, and Jianhu County People's Hospital—between May 11, 2006 and September 10, 2025 were enrolled. Multiple imputation was used to handle missing data. Kaplan‑Meier method and Cox regression analysis were employed to identify prognostic factors, and least absolute shrinkage and selection operator Cox (LASSO‑Cox) regression was applied to construct a risk score model. Propensity score matching (PSM) was performed to balance baseline differences between groups. A two‑sided P < 0.05 was considered statistically significant.Results: By the last follow‑up, the median overall survival (OS) of the entire cohort was 19.5 months, and the median progression‑free survival (PFS) was 12.8 months. Before and after PSM, no significant differences in OS or PFS were observed between the upfront chemoradiotherapy group and the surgery group (all P > 0.05); however, after matching, the chemoradiotherapy group demonstrated a survival benefit over the surgery group (OS: hazard ratio [HR] = 2.002, P < 0.05). The upfront systemic therapy alone group showed significantly worse prognosis compared with the above two groups (OS: HR = 2.28, P < 0.001). Multivariable Cox regression analysis identified systemic therapy alone and extensive‑stage disease according to the Veterans Administration Lung Study Group (VALSG) staging system as independent unfavorable prognostic factors for OS. The LASSO‑Cox risk score—incorporating chromogranin A (CgA) and Ki‑67 for the OS model, and synaptophysin (Syn), CgA, and Ki‑67 for the PFS model—significantly distinguished high‑risk from low‑risk groups (all P < 0.05), with CgA being the most stable prognostic marker across models (selected in 100% of the five imputed datasets). Patients receiving ≥ 4 cycles of chemotherapy had significantly superior OS compared with those receiving < 4 cycles (HR = 0.674, P = 0.013), while no significant difference in efficacy was observed between the etoposide plus platinum (EP) regimen and non‑EP regimens (P > 0.05).Conclusion: Among patients with PSCCE across different stages, upfront chemoradiotherapy and surgery yield comparable survival outcomes, both significantly superior to systemic therapy alone. Extensive‑stage VALSG stage and systemic therapy alone are independent unfavorable prognostic factors. The LASSO risk score based on CgA and Ki‑67 possesses independent prognostic value, with CgA serving as a stable and reliable neuroendocrine prognostic marker in PSCCE. A total of ≥ 4 cycles of chemotherapy (adequate chemotherapy) significantly improves OS.
- 4 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTreatment Patterns and Neuroendocrine Markers in Esophageal Small Cell Carcinoma: A Multicenter Retrospective Study
Objective: To evaluate the treatment patterns, prognostic factors, and the prognostic value of neuroendocrine markers in primary small cell carcinoma of the esophagus (PSCCE).Methods: A total of 217 patients with PSCCE treated at three centers—the Affiliated Cancer Hospital of Nanjing Medical University, the Affiliated Taizhou Hospital of Nanjing Medical University, and Jianhu County People's Hospital—between May 11, 2006 and September 10, 2025 were enrolled. Multiple imputation was used to handle missing data. Kaplan‑Meier method and Cox regression analysis were employed to identify prognostic factors, and least absolute shrinkage and selection operator Cox (LASSO‑Cox) regression was applied to construct a risk score model. Propensity score matching (PSM) was performed to balance baseline differences between groups. A two‑sided P < 0.05 was considered statistically significant.Results: By the last follow‑up, the median overall survival (OS) of the entire cohort was 19.5 months, and the median progression‑free survival (PFS) was 12.8 months. Before and after PSM, no significant differences in OS or PFS were observed between the upfront chemoradiotherapy group and the surgery group (all P > 0.05); however, after matching, the chemoradiotherapy group demonstrated a survival benefit over the surgery group (OS: hazard ratio [HR] = 2.002, P < 0.05). The upfront systemic therapy alone group showed significantly worse prognosis compared with the above two groups (OS: HR = 2.28, P < 0.001). Multivariable Cox regression analysis identified systemic therapy alone and extensive‑stage disease according to the Veterans Administration Lung Study Group (VALSG) staging system as independent unfavorable prognostic factors for OS. The LASSO‑Cox risk score—incorporating chromogranin A (CgA) and Ki‑67 for the OS model, and synaptophysin (Syn), CgA, and Ki‑67 for the PFS model—significantly distinguished high‑risk from low‑risk groups (all P < 0.05), with CgA being the most stable prognostic marker across models (selected in 100% of the five imputed datasets). Patients receiving ≥ 4 cycles of chemotherapy had significantly superior OS compared with those receiving < 4 cycles (HR = 0.674, P = 0.013), while no significant difference in efficacy was observed between the etoposide plus platinum (EP) regimen and non‑EP regimens (P > 0.05).Conclusion: Among patients with PSCCE across different stages, upfront chemoradiotherapy and surgery yield comparable survival outcomes, both significantly superior to systemic therapy alone. Extensive‑stage VALSG stage and systemic therapy alone are independent unfavorable prognostic factors. The LASSO risk score based on CgA and Ki‑67 possesses independent prognostic value, with CgA serving as a stable and reliable neuroendocrine prognostic marker in PSCCE. A total of ≥ 4 cycles of chemotherapy (adequate chemotherapy) significantly improves OS.
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12922-12925
Neoadjuvant immunochemotherapy with or without radiotherapy for locally advanced esophageal squamous cell carcinoma: a pooled analysis of two prospective single-arm clinical trials
- 17 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (6) , 12922-12925
Open AccessNeoadjuvant immunochemotherapy with or without radiotherapy for locally advanced esophageal squamous cell carcinoma: a pooled analysis of two prospective single-arm clinical trials
- Open Access
- 28 August 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
Salvage involved-field versus extended-field chemoradiotherapy for postoperative lymph node metastasis in esophageal squamous cell carcinoma: a retrospective clinical study
Esophageal cancer is a major global health threat, causing over 187,000 deaths in China in 2022. Esophageal squamous cell carcinoma (ESCC) patients face high recurrence risks postradical esophagectomy, with 28.5% − 54% experiencing relapse. Current guidelines lack strong evidence for salvage treatments. Although salvage concurrent chemoradiotherapy has shown potential in improving outcomes, the optimal irradiation fields remain unclear. Therefore, this study aimed to compare salvage involved-field irradiation (IFI) versus extended-field irradiation (EFI) with concurrent chemoradiotherapy in postoperative thoracic ESCC patients with lymph node metastases, assessing whether IFI reduces toxicity without compromising efficacy. This retrospective study included 106 patients (2015–2024) treated with IFI (targeting involved nodes) or EFI (involved nodes + prophylactic areas) plus concurrent chemotherapy. Outcomes included local control rate (LCR), disease-free survival (DFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), adverse events (CTCAE v5.0), and elective nodal control (ENC, IFI group). With 57.2-month median follow-up, IFI and EFI showed comparable media OS (63.2 vs. 59.5 months, P = 0.519) and media DFS (28.4 vs. 17.8 months, P = 0.334). IFI achieved higher 3-/5-year LCR (81.1% vs. 61.8%; 60.8% vs. 49.4%, P = 0.026) and lower Grade 1–2 radiation esophagitis (29.3% vs. 46.9%), pneumonia (25.8% vs. 40.8%), and Grade 3–4 toxicity (32.8% vs. 57.1%, all P < 0.05). No significant differences in ORR/DCR were observed. IFI’s ENC was 10.5% (6/57). Salvage IFI demonstrates non-inferior efficacy to EFI with significantly reduced severe toxicity (32.8% vs. 57.1%, P = 0.011) and potential survival benefits in single-node metastases, supporting its clinical prioritization. This retrospective study was approved by the Ethics Committee of Jiangsu Cancer Hospital (Ethical Approval No. [KY-2024-020]).
- 28 August 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
Open AccessSalvage involved-field versus extended-field chemoradiotherapy for postoperative lymph node metastasis in esophageal squamous cell carcinoma: a retrospective clinical study
Esophageal cancer is a major global health threat, causing over 187,000 deaths in China in 2022. Esophageal squamous cell carcinoma (ESCC) patients face high recurrence risks postradical esophagectomy, with 28.5% − 54% experiencing relapse. Current guidelines lack strong evidence for salvage treatments. Although salvage concurrent chemoradiotherapy has shown potential in improving outcomes, the optimal irradiation fields remain unclear. Therefore, this study aimed to compare salvage involved-field irradiation (IFI) versus extended-field irradiation (EFI) with concurrent chemoradiotherapy in postoperative thoracic ESCC patients with lymph node metastases, assessing whether IFI reduces toxicity without compromising efficacy. This retrospective study included 106 patients (2015–2024) treated with IFI (targeting involved nodes) or EFI (involved nodes + prophylactic areas) plus concurrent chemotherapy. Outcomes included local control rate (LCR), disease-free survival (DFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), adverse events (CTCAE v5.0), and elective nodal control (ENC, IFI group). With 57.2-month median follow-up, IFI and EFI showed comparable media OS (63.2 vs. 59.5 months, P = 0.519) and media DFS (28.4 vs. 17.8 months, P = 0.334). IFI achieved higher 3-/5-year LCR (81.1% vs. 61.8%; 60.8% vs. 49.4%, P = 0.026) and lower Grade 1–2 radiation esophagitis (29.3% vs. 46.9%), pneumonia (25.8% vs. 40.8%), and Grade 3–4 toxicity (32.8% vs. 57.1%, all P < 0.05). No significant differences in ORR/DCR were observed. IFI’s ENC was 10.5% (6/57). Salvage IFI demonstrates non-inferior efficacy to EFI with significantly reduced severe toxicity (32.8% vs. 57.1%, P = 0.011) and potential survival benefits in single-node metastases, supporting its clinical prioritization. This retrospective study was approved by the Ethics Committee of Jiangsu Cancer Hospital (Ethical Approval No. [KY-2024-020]).
- Open Access
- 7 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (10) , 2024-2033
Radiation Dose–Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy
Purpose: A preclinical model found that elective nodal irradiation attenuated the efficacy of radiotherapy (RT) and radio-immunotherapy. However, limited clinical studies have explored the correlation between radiation dose–volume parameters of negative tumor-draining lymph nodes (TDLN) and T-cell activation/prognosis for patients with cancer treated with definitive radiochemotherapy. Experimental Design: Patients with locally advanced esophageal cancer undergoing definitive chemoradiotherapy (CRT) were selected from two prospective trials. Dose–volume parameters of TDLN as well as other lymphocyte-related organs at risk and lymphocyte subsets such as CD3−CD19+ B cells, CD8+CD28+ T cells, and activated T cells (CD3+CD8+HLA-DR+) before and at the end of RT were collected. Logistic analysis was utilized to correlate dose–volume parameters with reductions in lymphocyte subsets. Prognosis of TDLN irradiation was investigated through Kaplan–Meier analysis and Cox hazards models. Results: Among 512 patients, the median mean dose of TDLN and negative non-TDLN was 25.6 and 15.1 Gy, respectively. Multivariable analyses indicated that TDLN V15 >50% was an independent predictor of poorer local recurrence–free survival (HR, 1.31; P = 0.029) and distant metastasis–free survival (HR, 1.39; P < 0.001), as well as greater reductions in CD3−CD19+ B cells (OR, 1.98; P = 0.002), CD8+CD28+ T cells (OR, 3.42; P < 0.001), and CD3+CD8+HLA-DR+ T cells (OR, 4.67; P = 0.002) after RT. Conclusions: A higher radiation dose–volume parameter of TDLNs in patients with esophageal cancer undergoing CRT was significantly associated with suppression of T-cell activation and a worse prognosis. Limiting the percentage of TDLN V15 may be beneficial for improving the prognosis of CRT with or without PD-1 inhibitors.
- 7 March 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (10) , 2024-2033
Open AccessRadiation Dose–Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy
Purpose: A preclinical model found that elective nodal irradiation attenuated the efficacy of radiotherapy (RT) and radio-immunotherapy. However, limited clinical studies have explored the correlation between radiation dose–volume parameters of negative tumor-draining lymph nodes (TDLN) and T-cell activation/prognosis for patients with cancer treated with definitive radiochemotherapy. Experimental Design: Patients with locally advanced esophageal cancer undergoing definitive chemoradiotherapy (CRT) were selected from two prospective trials. Dose–volume parameters of TDLN as well as other lymphocyte-related organs at risk and lymphocyte subsets such as CD3−CD19+ B cells, CD8+CD28+ T cells, and activated T cells (CD3+CD8+HLA-DR+) before and at the end of RT were collected. Logistic analysis was utilized to correlate dose–volume parameters with reductions in lymphocyte subsets. Prognosis of TDLN irradiation was investigated through Kaplan–Meier analysis and Cox hazards models. Results: Among 512 patients, the median mean dose of TDLN and negative non-TDLN was 25.6 and 15.1 Gy, respectively. Multivariable analyses indicated that TDLN V15 >50% was an independent predictor of poorer local recurrence–free survival (HR, 1.31; P = 0.029) and distant metastasis–free survival (HR, 1.39; P < 0.001), as well as greater reductions in CD3−CD19+ B cells (OR, 1.98; P = 0.002), CD8+CD28+ T cells (OR, 3.42; P < 0.001), and CD3+CD8+HLA-DR+ T cells (OR, 4.67; P = 0.002) after RT. Conclusions: A higher radiation dose–volume parameter of TDLNs in patients with esophageal cancer undergoing CRT was significantly associated with suppression of T-cell activation and a worse prognosis. Limiting the percentage of TDLN V15 may be beneficial for improving the prognosis of CRT with or without PD-1 inhibitors.
- Open Access
- 14 September 2024
- Published by Elsevier in Translational Oncology
- Vol. 50, 102123
Efficacy and safety of concurrent chemoradiotherapy with paclitaxel-based or S-1 regimens in treating elderly patients with esophageal squamous cell carcinoma: A multi-center propensity-score matched study
- 14 September 2024
- Published by Elsevier in Translational Oncology
- Vol. 50, 102123
Open AccessEfficacy and safety of concurrent chemoradiotherapy with paclitaxel-based or S-1 regimens in treating elderly patients with esophageal squamous cell carcinoma: A multi-center propensity-score matched study
- Open Access
- 29 August 2024
- Published by Springer Nature in Radiation Oncology
- Vol. 19 (1) , 1-11
Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older
Explore the efficacy and safety of involved-field irradiation (IFI) combined with S-1 as definitive concurrent chemoradiotherapy (dCRT) for locally advanced elderly esophageal squamous cell carcinoma (ESCC), under the premise of intensity-modulated radiotherapy (IMRT). We designed a prospective single-arm phase II study. The study enrolled 91 patients aged 75 to 92 years. Eligible participants had histologically confirmed squamous cell carcinoma, stage II to IV disease based on the 8th edition of the American Joint Committee on Cancer (AJCC). All elderly patients (EPs) received dCRT with S-1. which was administered orally twice daily for 28 days. The radiotherapy dose was 61.2 Gy delivered in 34 fractions or 50.4 Gy delivered in 28 fractions. The primary endpoint was 2-year overall survival (OS), and the secondary endpoints were progression-free survival (PFS), local control rate (LCR), and safety. From July 2017 to July 2021, we enrolled EPs with ESCC who were treated at the Jiangsu Cancer hospital. As of August 1, 2023, the median follow-up of surviving EPs was 31.4 months (IQR: 25.2 to 72.6 months). 83 patients (91.2%) completed the whole course of treatment. The 2-year OS rate was 59.2%, and the PFS rate was 43.7%. The most common grade 1 to 2 adverse effects (AEs) were radiation esophagitis (79.1%), and then were radiation pneumonia (46.2%). Anemia (41.8%) was the most common of grade 1 to 2 hematologic toxicity. The incidence of grade 3 or above AEs was 24.2%, and the incidence of leukopenia was the highest (11.0%). There was not one death due to treatment-related toxicity. In a subgroup analysis of radiotherapy doses, we found no statistically significant differences in PFS (P = 0.465) and OS (P = 0.345) in EPs with ESCC who received 50.4 Gy and 61.2 Gy, and that patients in the 50.4 Gy group had lower dermatitis (P = 0.045) and anemia (P = 0.004). IF-IMRT combined with S-1 is a promising regimen for elderly ESCC. And the radiotherapy dose of 50.4 Gy remains the standard dose for EPs with ESCC undergoing CCRT.
- 29 August 2024
- Published by Springer Nature in Radiation Oncology
- Vol. 19 (1) , 1-11
Open AccessRadiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older
Explore the efficacy and safety of involved-field irradiation (IFI) combined with S-1 as definitive concurrent chemoradiotherapy (dCRT) for locally advanced elderly esophageal squamous cell carcinoma (ESCC), under the premise of intensity-modulated radiotherapy (IMRT). We designed a prospective single-arm phase II study. The study enrolled 91 patients aged 75 to 92 years. Eligible participants had histologically confirmed squamous cell carcinoma, stage II to IV disease based on the 8th edition of the American Joint Committee on Cancer (AJCC). All elderly patients (EPs) received dCRT with S-1. which was administered orally twice daily for 28 days. The radiotherapy dose was 61.2 Gy delivered in 34 fractions or 50.4 Gy delivered in 28 fractions. The primary endpoint was 2-year overall survival (OS), and the secondary endpoints were progression-free survival (PFS), local control rate (LCR), and safety. From July 2017 to July 2021, we enrolled EPs with ESCC who were treated at the Jiangsu Cancer hospital. As of August 1, 2023, the median follow-up of surviving EPs was 31.4 months (IQR: 25.2 to 72.6 months). 83 patients (91.2%) completed the whole course of treatment. The 2-year OS rate was 59.2%, and the PFS rate was 43.7%. The most common grade 1 to 2 adverse effects (AEs) were radiation esophagitis (79.1%), and then were radiation pneumonia (46.2%). Anemia (41.8%) was the most common of grade 1 to 2 hematologic toxicity. The incidence of grade 3 or above AEs was 24.2%, and the incidence of leukopenia was the highest (11.0%). There was not one death due to treatment-related toxicity. In a subgroup analysis of radiotherapy doses, we found no statistically significant differences in PFS (P = 0.465) and OS (P = 0.345) in EPs with ESCC who received 50.4 Gy and 61.2 Gy, and that patients in the 50.4 Gy group had lower dermatitis (P = 0.045) and anemia (P = 0.004). IF-IMRT combined with S-1 is a promising regimen for elderly ESCC. And the radiotherapy dose of 50.4 Gy remains the standard dose for EPs with ESCC undergoing CCRT.
- 15 August 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 141, 112939
Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer
- 15 August 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 141, 112939
Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer
- Open Access
- 27 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 138, 112558
Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study
- 27 June 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 138, 112558
Open AccessEfficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study